NCT05629325View on ClinicalTrials.gov

Buspirone for Weak or Absent Esophageal Peristalsis

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Dysphagia, Esophageal
Interventions
DRUG

Buspirone Hydrochloride 10 MG

4 weeks of treatment with buspirone

DRUG

Placebo

4 weeks of treatment with placebo

Trial Locations (1)

3000

RECRUITING

University Hospitals Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER